In terms of assessing treatment efficacy, research indicates that ctDNA surpasses high PD-L1 expression, MSI-H, and TMB-H in dynamically monitoring the treatment response to immunotherapy, even in CEA-negative colorectal tumors (32). Here, CD274 is linked to colorectal neoplasm.